Loading
Life sciences · Journal article
Diabetes Obesity and Metabolism · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.71510. Figure S1: (a, b) Individual Binge Eating Scale (BES) trajectories from baseline to follow-up in the AOM + PS group (n = 29) and the PS-alone group (n = 12); the dashed line marks the BES = 17 threshold and thick lines are group means. (c) Response rates with 95% confidence intervals for the overall AOM group, controls and the semaglutide and tirzepatide subgroups. Response was defined a priori as a follow-up BES < 17 or a reduction of at least 50% from baseline; the AOM-versus-control difference was borderline (Fisher p = 0.052) and the semaglutide-versus-tirzepatide difference was non-significant (Fisher p = 0.63). (d) Mean percentage change from baseline (T1–T0) for anthropometric, behavioural and metabolic measures in each group; blue indicates a decrease and red an increase. AOM, anti-obesity medication; AST/ALT, aminotransferases; GGT, gamma-glutamyl transferase; HOMA-IR, homeostatic model assessment of insulin resistance; PS, psychological support; TG, triglycerides. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.